EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieVergleichsstudie

Survival with Osimertinib plus Chemotherapy in EGFR -Mutated Advanced NSCLC

Pasi A Jänne, David Planchard, Kunihiko Kobayashi, James Chih-Hsin Yang, Ying Liu, Natalia Valdiviezo, Tae Min Kim iD, Liyan Jiang, Hiroshi Kagamu, Noriko Yanagitani, Jialei Wang, Bivas Biswas iD und 11 weitere

New England Journal of Medicine · 01.01.2026 · 394 (1) · 27-38

DOI: 10.1056/nejmoa2510308 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 01.01.2026. Verfasst von Pasi A Jänne und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston. Hauptthemen laut MEDLINE: Acrylamides, Aniline Compounds, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 141-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcrylamidesAniline CompoundsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungLung NeoplasmsIndolesPyrimidinesAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedCarboplatinCisplatinErbB ReceptorsMutationPemetrexedProgression-Free Survival

Substanzen

AcrylamidesAniline CompoundsCarboplatinCisplatinEGFR protein, humanErbB ReceptorsosimertinibPemetrexedIndolesPyrimidines

Autor:innen und Institutionen

  • Department of Medical Oncology, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston.
  • Department of Medical Oncology, Institut Gustave Roussy, Thoracic Unit, Villejuif, France.
  • Faculty of Medicine, Université Paris-Saclay, Paris.
  • Department of Respiratory Medicine, Saitama Medical University International Medical Center, Hidaka, Japan.
  • Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
  • Graduate Institute of Oncology, National Taiwan University, Taipei, Taiwan.

ORCID-Profile: Tae Min Kim, Bivas Biswas, Carles Escriu

Förderung

  • AstraZeneca

Zitieren

APA

Jänne, P. A., Planchard, D., Kobayashi, K., Yang, J. C., Liu, Y., Valdiviezo, N., Kim, T. M., Jiang, L., Kagamu, H., Yanagitani, N., Wang, J., Biswas, B., Poltoratskiy, A., Neron, Y., Rojas, C., Koubkova, L., Escriu, C., Ezeife, D. A., Mann, H., …, & FLAURA2 Investigators (2026). Survival with Osimertinib plus Chemotherapy in EGFR -Mutated Advanced NSCLC. New England Journal of Medicine, 394(1), 27-38. https://doi.org/10.1056/nejmoa2510308

Vancouver

Jänne PA, Planchard D, Kobayashi K, Yang JC, Liu Y, Valdiviezo N, et al. Survival with Osimertinib plus Chemotherapy in EGFR -Mutated Advanced NSCLC. New England Journal of Medicine. 2026;394(1):27-38. doi:10.1056/nejmoa2510308

BibTeX
@article{Jnne2026,
  author = {Jänne, Pasi A and Planchard, David and Kobayashi, Kunihiko and Yang, James Chih-Hsin and Liu, Ying and Valdiviezo, Natalia and Kim, Tae Min and Jiang, Liyan and Kagamu, Hiroshi and Yanagitani, Noriko and Wang, Jialei and Biswas, Bivas and Poltoratskiy, Artem and Neron, Yeni and Rojas, Carlos and Koubkova, Leona and Escriu, Carles and Ezeife, Doreen A and Mann, Helen and Armenteros-Monterroso, Elena and Rukazenkov, Yuri and Lee, Chee Khoon and FLAURA2 Investigators, FLAURA2 Investigators},
  title = {Survival with Osimertinib plus Chemotherapy in EGFR -Mutated Advanced NSCLC},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {394},
  number = {1},
  pages = {27--38},
  doi = {10.1056/nejmoa2510308}
}
Kostenlos starten →